Description In vitro In vivo
ChemicalBook > CAS DataBase List > Tivozanib

Tivozanib

Description In vitro In vivo
Product Name
Tivozanib
CAS No.
475108-18-0
Chemical Name
Tivozanib
Synonyms
AV951;CS-8;AV-951;KRN-951;Tivozanib;TIVOZANIB;AV951;AV-951|||KRN951;AV-951(Tivozanib);Tivozanib USP/EP/BP;Tivozanib(AV951,KRN951)
CBNumber
CB82484655
Molecular Formula
C22H19ClN4O5
Formula Weight
454.86
MOL File
475108-18-0.mol
More
Less

Tivozanib Property

Melting point:
>202°C (dec.)
Boiling point:
550.4±50.0 °C(Predicted)
Density 
1.421
storage temp. 
Refrigerator
solubility 
DMSO (Slightly), Methanol (Slightly, Heated)
form 
White powder.
pka
11.74±0.70(Predicted)
color 
Pale Beige to Light Brown
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

TRC
Product number
T447205
Product name
Tivozanib
Packaging
5mg
Price
$95
Updated
2021/12/16
ChemScene
Product number
CS-0103
Product name
Tivozanib
Purity
99.27%
Packaging
10mg
Price
$102
Updated
2021/12/16
Apolloscientific
Product number
BIFK0002
Product name
Tivozanib
Packaging
10mg
Price
$116
Updated
2021/12/16
Biosynth Carbosynth
Product number
BT160380
Product name
Tivozanib
Packaging
5mg
Price
$50
Updated
2021/12/16
ChemScene
Product number
CS-0103
Product name
Tivozanib
Purity
99.27%
Packaging
5mg
Price
$72
Updated
2021/12/16
More
Less

Tivozanib Chemical Properties,Usage,Production

Description

Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.

In vitro

AV-951 is a novel quinoline-urea derivative. AV-951 blocks VEGF-dependent activation of mitogen-activated protein kinases and proliferation of endothelial cells.

In vivo

In vivo studies show that AV-951 also decreases the micro vessel density and suppresses VEGFR2 phosphorylation levels in tumor xenografts, especially at a concentration of 1mg/kg (p.o. administration). AV-951 shows almost complete inhibition of tumor xenografts growth (TGI>85%) in athymic rats. Another study in rat peritoneal disseminated tumor model shows that AV-951 could prolong the survival of the tumor-bearing rats with the MST of 53.5 days. AV-951 displays antitumor activity against many human tumor xenografts including lung, breast, colon, ovarian, pancreas and prostate cancer.

Characteristics

Primary targets: VEGFR/multikinase
Class: receptor tyrosine kinase
Treatment: RCC
Elimination half-life = 111 h
Protein binding = >99%

Uses

Tivozanib also known as AV-951 is an orally bioavailable potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.

Uses

Tivozanib is known as an oral VEGF receptor tyrosine kinase inhibitor, exhibiting antitumor effects towards renal cell carcinoma.. Tivozanib suppresses angiogenesis by selectively inhibiting against vascular endothelial growth factor. Potent VEGFR inhibitor.

Definition

ChEBI: 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea is an aromatic ether.

brand name

FotivdaTM

Mechanism of action

Tivozanib is a  tyrosine kinase inhibitor that exerts its actions by inhibiting the  phosphorylation of vascular endothelial growth factor receptor  (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases such as c-kit  and platelet derived growth factor beta (PDGFR β).

Side effects

  • diarrhea
  • nausea
  • vomiting
  • fatigue
  • loss of appetite
  • weight loss
  • voice hoarseness
  • back pain
  • mouth sores
  • cough
  • shortness of breath

Synthesis

The synthesis of Tivozanib is as follows:
Phenyl chlorocarbonate (601 g) was added dropwise to 3-amino-5-methylisoxazole (377 g), pyridine (1215 g), and N,N-dimethylacetamide (4 L) at 0°C, and the mixture was stirred at 20°C for 2 hr. 4-[(4-Amino-3-chlorophenol)oxy]-6,7-dimethoxyquinoline (847 g) was added to the reaction solution, and the mixture was stirred at 80°C for 5 hr. The reaction solution was cooled to 5°C. Thereafter, methanol (8.5 L) and water (8.5 L) were added thereto, and the mixture was neutralized with an aqueous sodium hydroxide solution. The resultant precipitate was collected by filtration, and the filtered product was slurried in water (8.5 L) for washing. The slurry was filtered, and the filtered product was then dried under the reduced pressure to give Tivozanib (1002 g, yield 86.1%).

target

VEGFR-2

Tivozanib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Tivozanib Suppliers

ACTIVATE SCIENTIFIC GmbH
Tel
--
Fax
--
Email
info@activate-scientific.com
Country
Germany
ProdList
2856
Advantage
61
More
Less

View Lastest Price from Tivozanib manufacturers

shandong perfect biotechnology co.ltd
Product
Tivozanib 475108-18-0
Price
US $0.00/g
Min. Order
1g
Purity
98% HPLC
Supply Ability
1kg
Release date
2023-08-02
Career Henan Chemical Co
Product
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea 475108-18-0
Price
US $1.00/kg
Min. Order
1g
Purity
99%
Supply Ability
100KG
Release date
2018-12-19

475108-18-0, TivozanibRelated Search:


  • AV951 (KRN951, Tivozanib) (stopped use since the patent issue)
  • AV-951; KRN951; AV 951;AV951
  • CS-8
  • Tivozanib, AV951,N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea
  • AV951
  • AV-951
  • Tivozanib
  • N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea
  • AV-951(Tivozanib)
  • 1-(2-Chloro-4-(6,7-diMethoxyquinolin-4-yloxy)phenyl)-3-(5-Methylisoxazol-3-yl)urea
  • TIVOZANIB;AV951
  • KRN951, TIVOZANIB) (STOPPED USE SINCE THE PATENT ISSUE
  • N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzaMide
  • Krn-951 Urea, N-(2-chloro-4-((6,7-diMethoxy-4-quinolinyl)oxy)phenyl)-N'-(5-Methyl-3-isoxazolyl)-
  • Tivozanib(AV951,KRN951)
  • KRN-951
  • N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea Tivozanib (AV-951)
  • TIVOZANIB (AV-951);AV-951;AV951;AV 951
  • Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-
  • Tivozanib USP/EP/BP
  • N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-m...
  • VEGFR Tyrosine Kinase Inhibitor IV Tivozanib
  • Lactic Acid Impurity 21
  • N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea
  • AV-951|||KRN951
  • 475108-18-0
  • Inhibitors
  • Antineoplastic
  • API